A timely diagnosis of myocardial infarction

Biomarkers in Medicine

Volumn 4, Issue 3, 2010, Pages 385-393

  Shand, Ja ^a   Menown, Ib ^a   McEneaney, Dj ^a  

^a SOUTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

Author keywords

Acute coronary syndrome; Biomarker; Myocardial infarction

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; D DIMER; FATTY ACID BINDING PROTEIN; FIBRIN; GELATINASE B; GLYCOGEN PHOSPHORYLASE B; HEART TYPE FATTY ACID BINDING PROTEIN; MATRIX METALLOPROTEINASE; MYOGLOBIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GOLD STANDARD; HEART MUSCLE; HEART MUSCLE NECROSIS; HEMOSTASIS; HUMAN; INFLAMMATION; LABORATORY TEST; RECEIVER OPERATING CHARACTERISTIC; REVIEW;

BIOLOGICAL MARKERS; CD40 LIGAND; CHEST PAIN; FATTY ACID-BINDING PROTEINS; GLYCOGEN PHOSPHORYLASE; HUMANS; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; MYOGLOBIN; TROPONIN;

EID: 77953754731     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.16     Document Type: Review

References (73)

1. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A, Pajak A: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90(1), 583-612 (1994).
2. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Single Volume (7th Edition). Braunwald E, Zipes DP, Libby P, Bonow R (Eds). Saunders, London, UK (2004).
3. Swap CJ, Nagurney JT: Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. J. Am. Med. Assoc. 294, 2623-2629 (2005).
4. Speake D, Terry P: First ECG in chest pain. Emerg. Med. J. 18(1), 61-62 (2001).
5. McClelland A: Comparison of the 80-lead body surface map to physician and to 12-lead electrocardiogram in detection of acute myocardial infarction. Am. J. Cardiol. 92(3), 252-257 (2003).
6. Cury RC, Shash K, Nagurney JT et al.: Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department. Circulation 118(8), 837-844 (2008).
7. Eggers KM, Oldgren J, Nordenskjöld A, Lindahl B: Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am. Heart J. 148(4), 574-581 (2004).
8. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. Circulation 116(22), 2634-2653 (2007).
9. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L: Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J. Am. Coll. Cardiol. 38(4), 979-986 (2001).
10. Hamm CW, Heeschen C, Goldmann B et al.: Benefit of Abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N. Engl. J. Med. 340(21), 1623-1629 (1999).
11. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD: Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet receptor inhibition in ischemic syndrome management. Lancet 354(9192), 1757-1762 (1999).
12. Wallentin L, Swahn E, Kontny F, Husted S, Lagerqvist B, Stahle E: Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354(9180), 708-715 (1999).
13. Adams J, Abendschein D, Jaffe A: Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 88(2), 750-763 (1993).
14. Kagen L, Scheidt S, Roberts L, Porter A, Paul H: Myoglobinemia following acute myocardial infarction. Am. J. Med. 58(2), 177-182 (1975).
15. Cairns J, Missirlis E, Walker W: Usefulness of serial determinations of myoglobin and creatine kinase in serum compared for assessment of acute myocardial infarction. Clin. Chem. 29(3), 469-473 (1983).
16. Mair J, Morandell D, Genser N, Lechleitner P, Dienstl F, Puschendorf B: Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. Clin. Chem. 41(9), 1266-1272 (1995).
17. Gibler WB, Hoekstra JW, Weaver WD et al.: A randomized trial of the effects of early cardiac serum marker availability on reperfusion therapy in patients with acute myocardial infarction: the Serial Markers, Acute Myocardial Infarction and Rapid Treatment Trial (SMARTT). J. Am. Coll. Cardiol. 36(5), 1500-1506 (2000).
18. Isakov A, Shapira I, Burke M et al.: Serum myoglobin levels in patients with ischemic myocardial insult. Arch. Intern. Med. 148(8), 1762-1765 (1988).
19. Takala TES, Rahkila P, Hakala E, Vuori J, Puranen J, Väänä nen K: Serum carbonic anhydrase III, an enzyme of type I muscle fibres, and the intensity of physical exercise. Pflügers Arch. 413(5), 447-450 (1989).
20. Vuori J, Syrjala H, Vaananen HK: Myoglobin/carbonic anhydrase three ratio: highly specific and sensitive early indicator for myocardial damage in acute myocardial infarction. Clin. Chem. 42107-42109 (1996).
21. de Lemos JA, Morrow DA, Gibson CM et al.: The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes: results from the TIMI 11B and TACTICS-TIMI 18 studies. J. Am. Coll. Cardiol. 40(2), 238-244 (2002).
22. Glatz JFC, van der Vusse GJ, Simoons ML, Kragten JA, van Dieijen-Visser MP, Hermens WT: Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin. Chim. Acta 272(1), 87-92 (1998).
23. Okamoto F, Sohmiya K, Ohkaru Y et al.: Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin. Chem. Lab. Med. 38(3), 231-238 (2000).
24. Ecollan P, Collet J, Boon G et al.: Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay. Int. J. Cardiol. 119(3), 349-354 (2007).
25. McCann CJ, Glover BM, Menown I et al.: Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur. Heart J. 29(23), 2843-2850 (2008).
26. O'Donoghue M: Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 114(6), 550-557 (2006).
27. Kilcullen N, Viswanathan K, Das R et al.: Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J. Am. Coll. Cardiol. 50(21), 2061-2067 (2007).
28. Ishii J, Ozaki Y, Lu J et al.: Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin. Chem. 51(8), 1397-1404 (2005).
29. McCann CJ, Glover BM, Menown IB et al.: Prognostic value of a multimarker approach for patients presenting to hospital with acute chest pain. Am. J. Cardiol. 103(1), 22-28 (2009).
30. Entam ML, Kanike K, Goldstein MA et al.: Association of gylcogenolysis with cardiac sarcoplasmic reticulum. J. Biol. Chem. 251(10), 3140-3146 (1976).
31. Schulze W, Krause EG, Wollenberger A: On the fate of glycogen phosphorylase in the ischemic and infarcting myocardium. J. Mol. Cell. Cardiol. 2(3), 241-251 (1971).
32. Apple FS: Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin. Chem. 51(5), 810-824 (2005).
33. Michael LH, Hunt JR, Weilbaecher D et al.: Creatine kinase and phosphorylase in cardiac lymph: coronary occlusion and reperfusion. Am. J. Physiol. Heart Circ. Physiol. 248(3), H350-H359 (1985).
34. Rabitzsch G: Isoenzyme BB of glycogen phosphorylase B and myocardial infarction. Lancet 341(8851), 1032-1033 (1993).
35. Mair J, Puschendorf B, Smidt J et al.: Early release of glycogen phosphorylase in patients with unstable angina and transient ST-T alterations. Br. Med. J. 72(2), 125-127 (1994).
36. van der Putten RF, Glatz JF, Hermens WT: Plasma markers of activated hemostasis in the early diagnosis of acute coronary syndromes. Clin. Chim. Acta 371(1-2), 37-54 (2006).
37. Abe S, Maruyama I, Arima S et al.: Increased heparin-releasable platelet factor 4 and d-dimer in patients one month after the onset of acute myocardial infarction: persistent activation of platelets and the coagulation/ fibrinolytic system. Int. J. Cardiol. 47(Suppl. 1), S7-S12 (1994).
38. Menown IBA, Mathew TP, Gracey HM et al.: Prediction of Recurrent Events by d-dimer and Inflammatory Markers in Patients with Normal Cardiac Troponin I (PREDICT) study. Am. Heart J. 145(6), 986-992 (2003).
39. Hackett D, Davies G, Maseri A: Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur. Heart J. 9(12), 1317-1323 (1988).
40. Newby AC: Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 28(12), 2108-2114 (2008).
41. Morishige K, Shimokawa H, Matsumoto Y et al.: Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc. Res. 57(2), 572-585 (2003).
42. Sukhova GK, Schonbeck U, Rabkin E et al.: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99(19), 2503-2509 (1999).
43. Jones CB, Sane DC, Herrington DM: Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc. Res. 59(4), 812-823 (2003).
44. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM: Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation 91(8), 2125-2131 (1995).
45. Loftus IM, Naylor AR, Goodall S et al.: Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke 31(1), 40-47 (2000).
46. Kai H, Ikeda H, Yasukawa H et al.: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32(2), 368-372 (1998).
47. Schönbeck U, Libby P: The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58(1), 4-43 (2001).
48. Henn V, Slupsky JR, Grafe M et al.: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391(6667), 591-594 (1998).
49. Lutgens E, Gorelik L, Daemen MJ et al.: Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5(11), 1313-1316 (1999).
50. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394(6689), 200-203 (1998).
51. Schonbeck U, Mach F, Sukhova GK et al.: Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ. Res. 81(3), 448-454 (1997).
52. Graf D, Müller S, Korthäuer U, Kooten CV, Weise C, Kroczek RA: A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. 25(6), 1749-1754 (1995).
53. Heeschen C, Dimmler S, Hamm C et al.: Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348(12) 1104-1111 (2003). (Pubitemid 36337321)
54. Lawrence JB, Oxvig C, Overgaard MT et al.: The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc. Natl Acad. Sci. USA 96(6), 3149-3153 (1999).
55. Wald N, Stone R, Cuckle HS et al.: First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. BMJ 305(6844), 28-28 (1992).
56. Bayes-Genis A, Conover CA, Overgaard MT et al.: Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N. Engl. J. Med. 345(14), 1022-1029 (2001).
57. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM: Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J. Am. Coll. Cardiol. 45(2), 229-237 (2005).
58. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Ferrer J, Vargas M: Circulating pregnancy-associated plasma protein A is not an early marker of acute myocardial infarction. Clin. Biochem. 38(2), 180-182 (2005).
59. Laterza OF, Cameron SJ, Chappell D, Sokoll LJ, Green GB: Evaluation of pregnancy-associated plasma protein A as a prognostic indicator in acute coronary syndrome patients. Clin. Chim. Acta. 348(1-2), 163-169 (2004).
60. Qin QP, Kokkala S, Lund J: Immunoassays developed for pregnancy-associated plasma protein-a (PAPP-A) in pregnancy not recognize papp-a in acute coronary syndromes. Clin. Chem. 52(3), 398-404 (2006).
61. Terkelsen CJ, Oxvig C, Nørgaard BL et al.: Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration. Am. J. Cardiol. 103(1), 29-35 (2009).
62. Tertti R, Wittfooth S, Porela P, Airaksinen KE, Metsarinne K, Pettersson K: Intravenous administration of low molecular weight and unfractionated heparin elicits a rapid increase in serum pregnancy-associated plasma protein A. Clin. Chem. 55(6), 1214 (2009).
63. Keller T, Zeller T, Peetz D et al.: Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N. Engl. J. Med. 361(9), 868-877 (2009).
64. Reichlin T, Hochholzer W, Bassetti S et al.: Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N. Engl. J. Med. 361(9), 858-867 (2009).
65. Apple FS, Smith SW, Pearce LA, Ler R, Murakami MM: Use of the centaur TnI-ultra assay for detection of myocardial infarction and adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin. Chem. 54(4), 723-728 (2008).
66. Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van Dieijen-Visser M: Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin. Chem. 55(1), 101 (2009).
67. Melanson SE, Morrow DA, Jarolim P: Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am. J. Clin. Pathol. 128(2), 282-286 (2007).
68. Reichlin T, Hochholzer W, Stelzig C et al.: Incremental value of copeptin for rapid rule out of acute myocardial infarction. J. Am. Coll. Cardiol. 54(1), 60-68 (2009).
69. Mair J, Genser N, Maier J, Lechleitner P, Dienstl F, Puschendorf B: Markers of activated coagulation for early diagnosis of acute myocardial infarction. Clin. Chim. Acta 267(2), 239-245 (1997).
70. Hermans W, Pelsers M, Mullers-Boumans M, Zwann C: Combined use of markers of muscle necrosis and fibrinogen conversion in the early differentiation of myocardial infarction and unstable angina. Clin. Chem. 44(4), 890-892 (1998).
71. Bayes-Genis A, Mateo J, Santaló M et al.: d-dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am. Heart J. 140(3), 379-384 (2000).
72. Derhaschnig U, Laggner AN, Roggla M et al.: Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. Clin. Chem. 48(11), 1924-1930 (2002).
73. Van der Putten RF, Velthuis HT, Zwaan C, Aarden LA, Glatz JFC, Hermens WT: State and diagnostic value of plasma tissue factor in early-hospitalised patients with chest pain. Br. J. Haematol. 131(1), 91-99 (2005).